CAPR
Capricor Therapeutics, Inc.
$20.68
+0.07
(+0.34%)
Mkt Cap
945.43M
Volume
1,085,441
52W Range
4.3-40.37
Sector
Healthcare
Beta
0.42
EPS (TTM)
-2.32
P/E Ratio
-12.77
Revenue (TTM)
0
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 22.27M | 25.18M | 2.55M | 244,898 | 310,250 | 1.01M | 1.67M | 2.67M | 3.19M | 3.78M | 4.17M |
| Net Income | (105.04M) | (40.47M) | (22.29M) | (29.02M) | (20.02M) | (13.66M) | (7.64M) | (15.19M) | 2.43M | (18.81M) | (12.86M) | (6.22M) |
| EPS | -2.26 | -1.15 | -0.83 | -1.18 | -0.87 | -0.88 | -2.06 | -5.17 | 1.00 | -10.14 | -8.09 | -5.31 |
| Free Cash Flow | (72.72M) | (41.53M) | (27.64M) | 1.56M | (18.01M) | (10.60M) | (6.82M) | (14.18M) | (14.26M) | (16.00M) | (10.97M) | 772,131 |
| FCF / Share | -1.56 | -1.18 | -1.03 | 0.06 | -0.78 | -0.68 | -1.84 | -4.83 | -6.15 | -8.62 | -6.90 | 0.66 |
| Operating CF | (69.81M) | (40.00M) | (25.60M) | 4.92M | (16.81M) | (10.05M) | (6.82M) | (13.86M) | (14.23M) | (15.80M) | (10.82M) | 958,562 |
| Total Assets | 355.95M | 170.48M | 58.73M | 50.09M | 41.33M | 34.62M | 11.11M | 9.25M | 16.27M | 18.75M | 16.07M | 13.63M |
| Total Debt | 17.94M | 4.83M | 5.61M | 5.94M | 6.25M | 3.69M | 3.38M | 3.38M | 3.38M | 17.01M | 9.16M | 9.16M |
| Cash & Equiv | 287.85M | 11.29M | 14.69M | 9.60M | 34.89M | 32.67M | 3.90M | 4.26M | 6.14M | 3.20M | 5.57M | 8.03M |
| Book Value | 305.79M | 145.46M | 22.60M | 11.79M | 31.37M | 28.20M | 6.84M | 4.62M | 11.23M | (4.00M) | (1.03M) | (6.25M) |
| Return on Equity | -0.34 | -0.28 | -0.99 | -2.46 | -0.64 | -0.48 | -1.12 | -3.29 | 0.22 | N/A | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 11.13M | 2.26M | 3.97M | 4.91M | 12.09M | 6.19M | 3.92M |
| Net Income | (33.94M) | (30.17M) | (24.57M) | (25.91M) | (24.39M) | (7.12M) | (12.56M) | (11.00M) | (9.79M) | (762,089) | (6.39M) | (7.37M) |
| EPS | -0.59 | -0.62 | -0.54 | -0.57 | -0.53 | -0.16 | -0.38 | -0.35 | -0.31 | -0.02 | -0.25 | -0.29 |
| Free Cash Flow | (40.00M) | (28.69M) | (23.70M) | (21.57M) | (7.57M) | (15.53M) | (11.70M) | (12.37M) | (1.93M) | (12.32M) | (9.43M) | (9.65M) |
| FCF / Share | -0.70 | -0.59 | -0.52 | -0.47 | -0.17 | -0.44 | -0.35 | -0.39 | -0.06 | -0.46 | -0.37 | -0.38 |
| Operating CF | (29.25M) | (23.57M) | (19.69M) | (20.12M) | (6.43M) | (14.80M) | (11.64M) | (12.29M) | (1.27M) | (11.59M) | (8.79M) | (9.42M) |
| Total Assets | 326.28M | 355.95M | 126.44M | 133.57M | 153.77M | 170.48M | 92.95M | 38.28M | 49.44M | 58.73M | 37.15M | 46.01M |
| Total Debt | 21.12M | 17.94M | 17.92M | 4.42M | 4.63M | 4.83M | 5.02M | 5.21M | 5.40M | 5.61M | 5.79M | 5.60M |
| Cash & Equiv | 105.42M | 287.85M | 19.51M | 23.24M | 28.79M | 11.29M | 68.38M | 10.69M | 6.21M | 14.69M | 8.98M | 9.84M |
| Book Value | 278.70M | 305.79M | 83.87M | 104.98M | 127.65M | 145.46M | 68.26M | 11.50M | 18.43M | 22.60M | (1.79M) | 2.73M |
| Return on Equity | -0.12 | -0.10 | -0.29 | -0.25 | -0.19 | -0.05 | -0.18 | -0.96 | -0.53 | -0.03 | N/A | -2.70 |
CAPR News
What's Going On With Capricor Therapeutics Stock On Friday?
Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy
Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual Conference
Caprock Announces Closing of Private Placement
Early Warning Press Release - Frank Guillemette Announces Completion of Acquisition of Common Shares of Caprock Mining Corp.
Caprock Announces Proposed Private Placement
Caprock Announces Consistent High-Grade Intercepts from the Final Three Deep Drill Holes at Destiny, Including 8.32 g/t Au over 2.6m
Capricor Therapeutics Eyes FDA Approval Path for Duchenne Cell Therapy
Capricor Therapeutics, Inc. (CAPR) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Capricor Therapeutics to Present at Upcoming Investor Conferences